AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31418621
Drug: Topical cantharidin
RxNorm normalized name: cantharidin Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cantharidin (control group A)
Trial: 8480272
Drug: 0.5 gram
RxNorm normalized name: methionine 0.5 gram ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 gram of prophylactic imipenem administered intravenously every eight hours for two weeks
Trial: 2887081
Drug: Primidone (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primidone (62.5 mg X 1 up to 250 mg X 3 daily)
Trial: 2887081
Drug: Propranolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (20 mg X 3 daily)
Trial: 23804631
Drug: Asunaprevir 200
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Asunaprevir 200 mg twice daily + PEG-IFN + ribavirin
Trial: 23804631
Drug: Asunaprevir 600
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Asunaprevir 600 mg twice daily + PEG-IFN + ribavirin
Trial: 23804631
Drug: Asunaprevir 600
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Asunaprevir 600 mg once daily + PEG-IFN + ribavirin
Trial: 16790627
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 microg/kg initial dose followed by continuous infusion of 0.5 microg.kg(‐1).h(‐1))
Trial: 16790627
Drug: Propofol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3 mg/kg initial dose followed by continuous infusion of 100 microg.kg(‐1).min(‐1))
Trial: 12923821
Drug: DA agonist
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA agonist (lisuride=LIS)
Trial: 12923821
Drug: DA antagonist
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA antagonist (fluphenazine=FLU)
Trial: 8463932
Drug: Standard outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard outpatient treatment (Control)
Trial: 3517475
Drug: BAY m
RxNorm normalized name: ZINC OXIDE 94 mg in 1 mL TOPICAL LOTION [Cay Skin MoBay Mineral Sunscreen Drops SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY m 1099 (25, 50, 100, 200 mg)
Trial: 3517475
Drug: BAY o
RxNorm normalized name: Bay Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY o 1248 (10, 20, 40 mg)
Trial: 29194765
Drug: Toceranib (TOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toceranib (TOC) 2.75 mg/kg EOD
Trial: 29194765
Drug: Vinblastine (VBL)
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinblastine (VBL) 2.5 mg/m2 weekly × 4 then EOW
Trial: 24836151
Drug: Control agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control agents (moral information removed)
Trial: 20460548
Drug: Simvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (80 mg/d)
Trial: 12625145
Drug: Simultaneous dosing
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous dosing (artesunate 200 mg/d plus mefloquine 250 mg/d from day 1 to day 3)
Trial: 12625145
Drug: Sequential dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential dosing (artesunate 200 mg/d for 3 days plus mefloquine 250 mg on day 2 and 500 mg on day 3)
Trial: 12412178
Drug: Morphine mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine mouthwash (MO; 14 patients)
Trial: 12412178
Drug: Magic mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magic mouthwash (MG; 12 patients)
Trial: 8029260
Drug: High-dose human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose human leukocyte alpha-interferon (IFN-alpha) treatment
Trial: 2929931
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 2% lignocaine
Trial: 28333939
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg slow-release three times daily
Trial: 23459753
Drug: 4 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 × 20 g whey protein every 3 h (INT)
Trial: 23459753
Drug: 8 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 × 10 g whey protein every 1.5 h (PULSE)
Trial: 23459753
Drug: 2 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 40 g whey protein every 6 h (BOLUS)
Trial: 20809354
Drug: Telephone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone administered cognitive behavioral therapy
Trial: 20809354
Drug: Telephone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone administered supportive emotion‐focused therapy
Trial: 19356666
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy using 'Photogem'
Trial: 17123204
Drug: Robot-assisted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted treatment (all types)
Trial: 12827582
Drug: Alfentanil 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 10 micro g/kg
Trial: 12827582
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 micro g/kg
Trial: 12827582
Drug: Remifentanil 2
RxNorm normalized name: remifentanil 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2 micro g/kg
Trial: 10747343
Drug: Carvedilol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25 mg twice daily for 5 months)
Trial: 9373227
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition by central venous catheter
Trial: 1539787
Drug: Oral airways
RxNorm normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral airways
Trial: 21971750
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection (Control group)
Trial: 18474534
Drug: Early Gp
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Gp IIb-IIIa inhibitors
Trial: 11794455
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen at 10 L/min through a facemask
Trial: 1791060
Drug: Dextroamphetamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (5 and 10 mg orally, 1 hr prior to test)
Trial: 9481526
Drug: Walnut diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut diet (78 g/d walnuts)
Trial: 7990368
Drug: Multimodality treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality treatment with laser
Trial: 7990368
Drug: Drug monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug monotherapy (Control)
Trial: 2499443
Drug: Glyburide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide (15 mg/day)
Trial: 25346499
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg once daily for five days followed by 15 mg or 20 mg once daily)
Trial: 25346499
Drug: Dose-adjusted warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted warfarin (coadministration of aspirin 100 mg per day until achieving international normalized ratio of 1.7)
Trial: 23788287
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) for thromboprophylaxis
Trial: 23788287
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin for thromboprophylaxis
Trial: 19597914
Drug: Topical imiquimod
RxNorm normalized name: imiquimod Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod 5% cream plus Nd:YAG laser treatment
Trial: 19597914
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream plus Nd:YAG laser treatment
Trial: 17409018
Drug: Ribavirin, 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin, 1000 mg daily (n=7)
Trial: 17409018
Drug: Ribavirin, 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin, 1000 mg daily + Amantadine, 200 mg daily (n=8)
Trial: 17409018
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (controls, n=26)
Trial: 17409018
Drug: Ribavirin and
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin and Amantadine (combined treatment)
Trial: 9891831
Drug: Cibenzoline (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (130 mg twice daily)
Trial: 9891831
Drug: Disopyramide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide (250 mg slow release twice daily)
Trial: 7636755
Drug: Remoxipride administered
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride administered at 5 different time intervals (2, 8, 12, 24, and 48 hr)
Trial: 81361
Drug: 900 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg/day oral DL-carnitine chloride
Trial: 81361
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of carnitine
Trial: 22123869
Drug: Acetaminophen administered
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen administered 30 minutes before immunization and every 4 hours thereafter for a total of 5 doses
Trial: 9065537
Drug: Acetaminophen use
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen use
Trial: 15349012
Drug: Venlafaxine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (75 to 112.5 mg/d)
Trial: 10396705
Drug: Pimobendan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan (2.5 or 5 mg daily)
Trial: 7587031
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g IV cefotaxime every 12 h
Trial: 7587031
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g IV ceftriaxone once daily
Trial: 2103060
Drug: Succinylcholine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.0 mg.kg‐1
Trial: 27909950
Drug: sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib 400 mg BID
Trial: 27909950
Drug: corticosteroid ointment
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corticosteroid ointment
Trial: 23662517
Drug: Abdominal cross
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abdominal cross section space (ACSB) blockade with non-opioid analgesics
Trial: 12070058
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) 500 microg twice daily via a dry powder inhaler
Trial: 10468683
Drug: ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine bismuth citrate (RBC) 400 mg with clarithromycin 500 mg
Trial: 10468683
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg with clarithromycin 500 mg
Trial: 2270564
Drug: 0.5% sanguinarine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% sanguinarine gel
Trial: 2270564
Drug: 0.05% and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% and 0.5% sanguinarine gel
Trial: 7214806
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravenous glucagon
Trial: 27837101
Drug: Exercise (6-month,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise (6-month, twice weekly programme: 30 min aerobic and 30 min resistance)
Trial: 27837101
Drug: Handwriting (6-month,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handwriting (6-month, twice weekly programme at home)
Trial: 23210726
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (300 mg single dose)
Trial: 23210726
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg twice daily for 3 days)
Trial: 21537018
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of oritavancin (200 mg for 3 to 7 days)
Trial: 21537018
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oritavancin (1,200 mg)
Trial: 21537018
Drug: Infrequent dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrequent dose of oritavancin (800 mg with an option for an additional 400 mg on day 5)
Trial: 21537018
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of oritavancin (200 mg) in MRSA patients
Trial: 21537018
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oritavancin (1,200 mg) in MRSA patients
Trial: 21537018
Drug: Infrequent dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrequent dose of oritavancin (800 mg with an option for an additional 400 mg on day 5) in MRSA patients
Trial: 19299779
Drug: Remifentanil (infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (infusion rate 0.014 +/- 0.011 microg x kg(‐1) x min(‐1))
Trial: 15293769
Drug: Newer antidepressant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer antidepressant agents
Trial: 15293769
Drug: Older antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older antidepressant agents
Trial: 9252005
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose alfentanil (100 microg kg(‐1) induction, 1‐2 microg kg(‐1) min(‐1) infusion)
Trial: 9252005
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose alfentanil (30 microg kg(‐1) induction, 10‐20 microg kg(‐1) bolus every hour)
Trial: 19333167
Drug: Gabapentin ER
RxNorm normalized name: gabapentin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin ER once daily (1800 mg PM)
Trial: 19333167
Drug: Gabapentin ER
RxNorm normalized name: gabapentin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin ER twice daily (600 mg AM, 1200 mg PM)
Trial: 17709449
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg selenium, and 20 mg zinc)
Trial: 7601181
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg bds)
Trial: 7601181
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg tds)
Trial: 28384800
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (200,000 IU initial dose, followed by 100,000 IU monthly)
Trial: 18285548
Drug: Maribavir 100
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir 100 mg twice daily
Trial: 12027147
Drug: Calcium-vitamin D
RxNorm normalized name: Calcium-Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-vitamin D (CaD) supplementation (calcium carbonate 500 mg, citric acid 2.175 gr, cholecalciferol 200 IU)
Trial: 12027147
Drug: Calcium (Ca)
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (Ca) supplementation (calcium gluconolactate and carbonate 500 mg)
Trial: 7572012
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of oral tizanidine
Trial: 7572012
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of oral tizanidine
Trial: 2144295
Drug: DHEA 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 1600 mg/day (in four divided doses) for 28 days
Trial: 377968
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of norgestimate (0.125 mg) and ethinyl estradiol (0.035 mg)
Trial: 377968
Drug: Various dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various dosage combinations of norgestimate and ethinyl estradiol
Trial: 31605392
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 5 mL
Trial: 31605392
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 15 mL
Trial: 31605392
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 20 mL
Trial: 31605392
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 30 mL
Trial: 23332872
Drug: TKI re-treatment
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI re-treatment (sunitinib, sorafenib, dovitinib) after everolimus
Trial: 11407727
Drug: Troglitazone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (200 mg bid)
Trial: 11407727
Drug: Glibenclamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (2.5 mg daily)
Trial: 9587532
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg per day for 4 weeks
Trial: 8460390
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplementation (4g Mg granulate verum, 6.7 mmol Mg aspartate)
Trial: 23979789
Drug: Dietary energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary energy density (kcal/g)
Trial: 21863204
Drug: Psychological treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatments (defined as interventions involving verbal communication between a therapist and a patient)
Trial: 17655736
Drug: Bed rest
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bed rest and concurrent exercise training countermeasure (BRE, n = 8)
Trial: 11716384
Drug: Posterior-stabilized AMK
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior-stabilized AMK total knee implants
Trial: 11716384
Drug: Cruciate-retaining AMK
RxNorm normalized name: Gentiana cruciata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cruciate-retaining AMK total knee implants
Trial: 2565729
Drug: Adrenaline 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 0.3 mg subcutaneously
Trial: 2565729
Drug: Adrenaline 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 0.3 mg subcutaneously preceded by ICI 118,551 5 mg orally
Trial: 2565729
Drug: Salbutamol 8
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 8 mg orally
Trial: 21257263
Drug: 1 tablet
RxNorm normalized name: Ovral-21 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of ibuprofen 200mg/paracetamol 500mg
Trial: 21257263
Drug: 2 tablets
RxNorm normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of ibuprofen 200mg/paracetamol 500mg
Trial: 21257263
Drug: 2 tablets
RxNorm normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of ibuprofen 200mg/codeine 12.8mg
Trial: 21257263
Drug: 2 tablets
RxNorm normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of paracetamol 500mg/codeine 15mg
Trial: 19320234
Drug: BILB 1941
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILB 1941 60 mg
Trial: 19320234
Drug: BILB 1941
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILB 1941 80 mg
Trial: 19320234
Drug: BILB 1941
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILB 1941 100 mg
Trial: 19320234
Drug: BILB 1941
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILB 1941 150 mg